According to the literature of 5-year survival rate for breast cancer is about 0,6-5%, and 10th 0.3-1.2%. This case showed that patients with breast cancer stage IV can survive by applying of all methods of treatment that in the arsenal of oncologists at present. Regarding the 2nd metachronous malignancy nonHodgkin's lymphoma - whether it is a consequence of genetic aberatsy or induced by previous treatment of breast cancer, the question remains open, because we have no way to genetic research. According danym E. Fearon (1995) gene mutation CG-CD1 are common for breast cancer and malignant lymphoma.